Lets Separate these subjects
Regarding Til: forget about if it's effective. That doesn't matter. The question is, how many other companies are out there already providing Til, and ahead of the curve on GNBP?
There are no other companies offering Tils. And having a product with successful Phase 2 clinical from independent institutions does matter. This is not a preclinical development product. Although you seem to "know" the ceo lets agree to separate discussions of the governance from the product development if any. So as information is released people can discuss it on this board in the absence of heated personal opinions about executives.
Don't you think their CD-55 patent is the "Contego" brand name they concocted? I do.
CD55 antibody and Contego are two completly different products. Seems you don't know what you are talking about?
That's the issue with their CD-55 antibody treatment. Turns out CD-55 is widely manufactured and offers no competitive advantage for GNBP. I can buy CD-55 over the internet from many labs. GNBP doesn't even have the ability to make CD-55.
Most companies outsource the production of monoclonal antibody humanization, production and manufacture. But this has nothing to do with Contego as I mentioned before.
We also know a lot about Tony Cataldo, and this is a repeat of what he always does; find a distressed company with worthless patent, and re-market it to make it look like a new, exciting breakthrough product. Then it turns out the patent is either expiring, or is is the same thing available by many competitors, or is already obsolete because others have already marketed something better.
Til are a valuable therapeutic option. Just ask any melanoma patient, or reader of the New England Journal of Medicine, Science Magazine, or Journal of Clinical Oncology. When dendreon generated a cell therapy product for prostate cancer, they had to brand it with a name "Provenge". So the name is irrelevant. Though you should know what they are naming -as indicated above-
News 
Market Data 
Discover 
